Figure 2
From: Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES
mRANTES and MIP-1β mRNA expression in non-inflamed and inflamed skins (a) Expression of mRANTES induced by different doses of shikonin (50 or 100 μg/site/mice) in non-inflamed skin and statistic analysis data; (b) Time course of shikonin-induced mRANTES mRNA expression in non-inflamed skin tissues. Shikonin was topically applied at 100 μg/site/mice. (c) Anti-inflammatory effect of shikonin on the mRNA expression of mRANTES and MIP-1β in a TPA-induced inflamed skin model and statistic analysis data. The results are representative of three independently performed experiments.